Lqt Therapeutics Announces Closing Of Us$19M Series A Financing To Advance Lead Compound Through Phase 1 While Advancing Portfolio Assets
Lqt Therapeutics Announces Closing Of Us$19M Series A Financing To Advance Lead Compound Through Phase 1 While Advancing Portfolio Assets
08/11/21, 1:14 PM
Location
lavalMoney raised
$19 million
Round Type
series a
LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the development of precision therapies for genetic heart diseases, today announced the successful completion of a US$19 million Series A financing. LQTT is advancing a series of in-licensed compounds discovered and developed by Sanofi S.A. (Paris, France) which inhibit Serum/Glucocorticoid Regulated Kinase 1 (SGK1)
Company Info
Location
laval, quebec, canada
Additional Info
LQT Therapeutics, Inc. is pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias based on research from Beth Israel Deacons Medical Center, Massachusetts General Hospital, and Sanofi, S.A. By combining leading-edge cardiovascular genetics and diagnostics with recent advances in the understanding of the role of SGK1, LQT Therapeutics seeks to make a meaningful difference in the lives of people suffering from Long QT Syndrome and resistant cancers. Launched in 2019 by the Fonds de solidariteĢ FTQ. LQT Therapeutics was founded by world-class experts in cardiovascular disease, cardiac muscle biology and drug development. For more information, please visit www.lqttrx.com